This difference in breakpoint distribution was not driven by the type of fusion (minor vs. Major BCR) as the difference between CML and ALL was still apparent when only Major BCR::ABL1-positive patients were analyzed (445 CML and 123 ALL; p = 2.11e-02). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.